Akshat Khurana
Interventional Cardiology · Boston, MANPI 1255013405
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,928 of the $11,354 with a category attached, or 69.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 19.5%. Reporting peaked in 2024 at $6,555 and has fallen 54.3% since, to $2,997 in 2025.
Across 252 payments — averaging $45.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abiomed$2K
- Abbott$2K
- Terumo Medical Corporation$889
- Medtronic$660
- Shockwave Medical, Inc$648
- plus $4K from 28 others
Across 2 payments — averaging $64.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$128
What the payments were for
- Speaking & faculty fees$9008%
- Travel & lodging$2,52422%
- Food & beverage$7,92870%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 32 | $2,210 |
| Abiomed | 15 | $1,814 |
| Abbott | 33 | $1,568 |
| Terumo Medical Corporation | 10 | $889 |
| Medtronic | 16 | $660 |
| Shockwave Medical, Inc | 16 | $648 |
| Bard Peripheral Vascular, Inc. | 13 | $376 |
| Chiesi USA, Inc. | 15 | $350 |
| Pfizer | 12 | $344 |
| Teleflex LLC | 5 | $331 |
| Cardiva Medical, Inc. | 13 | $325 |
| AstraZeneca | 14 | $271 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $168 |
| Angiodynamics, Inc. | 4 | $164 |
| Amgen | 6 | $163 |
| Penumbra, Inc. | 4 | $149 |
| Daiichi Sankyo Inc. | 5 | $123 |
| Cook Medical LLC | 4 | $122 |
| Cordis US CORP. | 4 | $92 |
| Philips North America LLC | 3 | $88 |
| Asahi Intecc USA, Inc. | 2 | $61 |
| Boehringer Ingelheim | 2 | $58 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Stryker | 2 | $43 |
| Inari Medical, Inc. | 1 | $43 |
| ZOLL Circulation Inc | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,354 in reported general payments places this provider in the 65th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 22 | $139 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Boston
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.